Sayfa yüklenirken bir hata oluştu.
Teknik ekibimiz bilgilendirildi, ancak sorunun devam etmesi durumunda lütfen e-posta destek widget ile bize ulaşın.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM EBIT Multiple | 27,4x - 30,3x | 28,9x |
| Selected Fwd EBIT Multiple | 10,5x - 11,6x | 11,1x |
| Fair Value | $86,03 - $100,65 | $93,34 |
| Upside | -39,1% - -28,8% | -34,0% |
| Benchmarks | Ticker | Full Ticker |
| Boston Scientific Corporation | BSX | NYSE:BSX |
| Integra LifeSciences Holdings Corporation | IART | NasdaqGS:IART |
| Haemonetics Corporation | HAE | NYSE:HAE |
| Integer Holdings Corporation | ITGR | NYSE:ITGR |
| Solventum Corporation | SOLV | NYSE:SOLV |
| ICU Medical, Inc. | ICUI | NasdaqGS:ICUI |
| - | - | - |
| Select LTM EBIT Multiple | |||||||
| Benchmark Companies | |||||||
| BSX | IART | HAE | ITGR | SOLV | ICUI | ||
| NYSE:BSX | NasdaqGS:IART | NYSE:HAE | NYSE:ITGR | NYSE:SOLV | NasdaqGS:ICUI | ||
| Historical EBIT Growth | |||||||
| 5Y CAGR | 10.4% | 2.0% | 7.1% | 5.6% | NM- | -7.8% | |
| 3Y CAGR | 18.1% | -3.1% | 30.5% | 16.0% | -16.5% | -11.7% | |
| Latest Twelve Months | 28.5% | -27.8% | 13.1% | 22.3% | -48.9% | 257.9% | |
| Historical EBIT Profit Margin | |||||||
| 5 Year Average Margin | 15.6% | 15.4% | 14.2% | 11.0% | 18.6% | 5.5% | |
| Prior Fiscal Year | 17.0% | 16.9% | 15.8% | 11.5% | 20.6% | 2.1% | |
| Latest Fiscal Year | 17.9% | 11.3% | 17.2% | 13.0% | 13.2% | 4.1% | |
| Latest Twelve Months | 18.5% | 10.6% | 17.2% | 13.3% | 10.5% | 5.0% | |
| Current Trading Multiples | |||||||
| EV / LTM Revenue | 9.58x | 1.73x | 3.37x | 3.18x | 2.43x | 1.98x | |
| EV / LTM EBITDA | 37.1x | 8.7x | 13.1x | 16.1x | 14.3x | 14.3x | |
| EV / LTM EBIT | 51.8x | 16.2x | 19.6x | 23.9x | 23.2x | 39.4x | |
| Low | Mid | High | |||||
| Benchmark EV / LTM EBIT | 16.2x | 23.2x | 51.8x | ||||
| Historical EV / LTM EBIT | 28.4x | 62.9x | 252.8x | ||||
| Selected EV / LTM EBIT | 27.4x | 28.9x | 30.3x | ||||
| (x) LTM EBIT | 121 | 121 | 121 | ||||
| (=) Implied Enterprise Value | 3,325 | 3,500 | 3,675 | ||||
| (-) Non-shareholder Claims * | (1,300) | (1,300) | (1,300) | ||||
| (=) Equity Value | 2,025 | 2,200 | 2,375 | ||||
| (/) Shares Outstanding | 24.6 | 24.6 | 24.6 | ||||
| Implied Value Range | 82.30 | 89.41 | 96.52 | ||||
| FX Rate: USD/USD | 1.0 | 1.0 | 1.0 | Market Price | |||
| Implied Value Range (Trading Cur) | 82.30 | 89.41 | 96.52 | 141.38 | |||
| Upside / (Downside) | -41.8% | -36.8% | -31.7% | ||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | BSX | IART | HAE | ITGR | SOLV | ICUI | |
| Enterprise Value | 167,442 | 2,775 | 4,581 | 5,537 | 20,201 | 4,780 | |
| (+) Cash & Short Term Investments | 725 | 273 | 307 | 32 | 534 | 298 | |
| (+) Investments & Other | 654 | 27 | 0 | 8 | 0 | 4 | |
| (-) Debt | (11,708) | (2,021) | (1,356) | (1,355) | (7,913) | (1,602) | |
| (-) Other Liabilities | (233) | 0 | 0 | 0 | 0 | 0 | |
| (-) Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 156,880 | 1,055 | 3,532 | 4,222 | 12,822 | 3,480 | |
| (/) Shares Outstanding | 1,479.4 | 77.7 | 50.2 | 34.9 | 173.0 | 24.6 | |
| Implied Stock Price | 106.04 | 13.57 | 70.31 | 120.99 | 74.11 | 141.38 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 106.04 | 13.57 | 70.31 | 120.99 | 74.11 | 141.38 | |
| Trading Currency | USD | USD | USD | USD | USD | USD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |